MSMB’s Shkreli Ousted From Pharma He Founded

Oct 1 2014 | 8:24am ET

Hedge-fund manager Martin Shkreli will have to go back to his day job.

The MSMB Capital Management chief was fired as CEO of pharmaceutical company Retrophin Inc. yesterday in the wake of its May deal to buy a potentially lucrative kidney medication. Shkreli, who founded Retrophin in 2011, follows CFO Marc Panoff and director Jeffrey Paley out the door.

Retrophin shares have nose-dived since the purchase of Thiola, whose price Shkreli said would be increased between 20- and 35-fold.

Shkreli said that in spite of his ouster he was sticking with his and MSMB’s 11% stake in the company.

“The stock is very, very cheap,” he wrote on Twitter. The forum was fitting: Shkreli has frequently gotten himself into trouble on the social-media site, and earlier this year Retrophin employees were caught impersonating rappers on Twitter to promote the company.


In Depth

PAAMCO: Will Inflation Deflate the Asset Bubble?

Jan 30 2018 | 9:49pm ET

As the U.S. shifts from monetary stimulus to fiscal stimulus, market pricing should...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Boost Hedge Fund Marketing ROI By Raising Your ROO

Feb 14 2018 | 9:57pm ET

Tasked with delivering returns on client capital, a common dilemma for many alternative...

 

FINalternatives Trending

From the current issue of